The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.
Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B., Spallone, V., et al. (2014). Benfotiamine: Commentary and update on recent studies. DIABETES, STOFFWECHSEL UND HERZ, 23(4), 203-206.
Benfotiamine: Commentary and update on recent studies
SPALLONE, VINCENZA;
2014-08-20
Abstract
The thiamine prodrug benfotiamine (S-benzoylthiamine-O-monophosphate) has been shown to prevent the formation of advanced glycation endproducts (AGEs), thus decreasing hyperglycaemia-induced damage and neuropathic sensory symptoms. However, recent studies have yielded contradictory results. Other studies emphasize the need for further research on the potential of benfotiamine in the treatment of vascular and diabetes complications. Currently, benfotiamine is considered to be a pathogenetic treatment in counteracting oxidative stress and hyperglycaemia-induced metabolic changes that lead to neuropathy.File | Dimensione | Formato | |
---|---|---|---|
StirbanA-SpalloneV.Diabetes, Stoffwechsel und Herz 2014.pdf
solo utenti autorizzati
Descrizione: Articolo preprint
Licenza:
Copyright dell'editore
Dimensione
405.99 kB
Formato
Adobe PDF
|
405.99 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.